Completed

At the dose tested, Baclofen did not have a significant effect on tremor, eye movement or balance deficits.

This open label study was performed to assess the safety and tolerability of the EryDex System in people with A-T.

These trials studied whether a low dose betamethasone would reduce neurological symptoms associated with A-T.

This trial was performed to see if amantadine sulphate improves ataxia or other movement disorders associated with A-T.

Among the 204 identified CSF proteins, 13 showed significant changes in A-T patients versus control samples.

Two laboratory markers of oxidative stress improved when participants took both alpha-lipoic acid and nicotinamide.

No overall consistent improvement in neurologic function was observed on L-Dopa.

This trial in the Netherlands looked at the effects of nicotinamide ribose as a potential treatment for people with A-T.

Participants with A-T demonstrated lower brain activity or metabolism in the cerebellum as compared to control participants.

This trial assessed the safety and efficacy of the EryDex System to treat neurological symptoms associated with A-T.